Wednesday, December 14, 2005 Poster Session

Total Page:16

File Type:pdf, Size:1020Kb

Wednesday, December 14, 2005 Poster Session Neuropsychopharmacology (2005) 30, S210-S270 © 2005 Nature Publishing Group All rights reserved 0893-133X/05 S210 www.neuropsychopharmacology.org Wednesday, December 14, 2005 2. White Matter Changes in Cocaine Dependence Poster Session III - Wednesday Jay Nierenberg*, Laurie Nash, Matthew J Hoptman, Jan Hrabe, Babak A Ardekani, Gregory Bunt, Kelvin O Lim and John Rotrosen 1. Design, Synthesis and Application of Novel Tropane-Based Nathan S. Kline Institute for Psychiatric Research, Orangeburg, Photoaffinity Labels Toward the Identification of Binding NY, USA Domains on the Dopamine Transporter Amy H Newman*, Mu-Fa Zou, Jianjing Cao, Joo H Cha, John R Sponsor: Travel Awardee, Young Investigator Memorial, 2005 Lever, Theresa Kopajtic, Jonathan L Katz, M. L Parnas and Roxanne Vaughan Background: Cocaine Dependence (CD) is a serious problem that Medicinal Chemistry Section, NIDA-IRP, NIH, Baltimore, MD, USA often is refractory to treatment. Evidence suggests that CD is associ- ated with white matter (WM) deficits that may underlie changes in Sponsor: Jonathan Javitch mood, cognition and behavior. We studied 46 patients with CD and 17 controls using MRI at 1.5T to better characterize WM abnormal- Background: Irreversible ligands, derived from tropane-based ities in CD and to test whether they were reversible. Diffusion ten- dopamine uptake inhibitors, have been designed to covalently bind to sor imaging (DTI) was used for measurements in WM. DTI is an discrete points of attachment on the dopamine transporter (DAT), via MRI method that provides measures (fractional anisotropy, FA) a photoactivated azido group. We previously have demonstrated that that are sensitive to WM pathology but do not provide insight into depending on the position of the azido substitution on the tropane ring underlying mechanisms, as well as measures, such as axial (Dax) system, covalent attachment can occur in different transmembrane re- and radial (Dra) diffusivity, which can reflect specific microstruc- gions suggesting that 1) the position of the azido attachment on the tural changes. tropane ring dictates transmembrane domain labeling and/or 2) not all Methods: Subjects were patients in a therapeutic community that tropane-based DAT inhibitors bind to the same recognition site(s) on closely monitored ongoing abstinence with random toxicology test- the DAT. Based on these early studies, we hypothesized that appending ing. Patients were subgrouped by duration of abstinence- <6 weeks azido groups at numerous positions on different tropane-based DAT (COC-S, n=15), 2-10 months (COC-M, n=15), > 1 year (COC-L, inhibitors (3-phenyl tropanes and benztropines) would provide the n=16)- and matched with non-using controls (CON). 8-direction opportunity to identify points of attachment on the DAT, elucidate 3D- DTI was acquired with a double spin echo, pulsed-gradient echo- arrangement of the transmembrane domains, and direct future drug planar imaging method that minimized distortion due to eddy cur- design. Herein, we report our progress in these pursuits. rents. DTI maps were analyzed using both voxelwise methods and Methods: All photoaffinity labels were designed to have azido groups region of interest (ROI) approaches in separate analyses. Thresh- attached to the N-, 2- or 3-position of the tropane ring of either the olding in voxelwise tests used a two-stage seed-cluster method that benztropine or 3-phenyltropane parent molecule. Synthetic strategies was designed to minimize false positive detections. Briefly absti- were undertaken based on modifications of previously published nent subjects (n=7) also were scanned longitudinally to test work (Agoston et al., 1997, Zou et al., 2001, 2003, Lever et al., 2005). whether cross-sectional differences were supported by changes in Radiolabel displacement studies using [3H]WIN 35,428 in rat cau- individuals. date putamen tissue were used to assess IC50 values of all final prod- Results: Subjects were well-matched on demographic variables. Num- ucts and their immediate precursors. ber of years of cocaine use was similar in user subgroups and averaged Results: We initially prepared an N-substituted benztropine-based ~10 years. When the whole CD cohort was compared with CON in photoaffinity label [125I]GA 2-34, which covalently attached to the voxelwise t-tests, patients showed mainly lower FA in most regions in 1-2 transmembrane spanning region of the DAT. This was compared which differences were found. In contrast, COC-S subjects showed and found to be in contrast to the 4-7 transmembrane spanning re- more WM voxels with higher than lower FA, though these were con- gion labeled by a 2-substituted-3-phenyltropane-based photoaffinity centrated in the inferior frontal WM. Whereas all patients showed sig- label, [125I]RTI 82 (Vaughan et al. 1999). Based on this early study nificantly higher FA in frontal WM regions bilaterally, COC-S subjects we then synthesized a derivative of RTI 82 that had the same N-sub- also showed higher FA in ventromedial prefrontal WM regions that stituent as GA 2-34 (Zou et al. 2001). The resulting [125I]MFZ 2-24 was not present in COC-L. COC-S subjects also showed higher FA in (Lever et al 2005) has now been discovered to covalently link to a dis- WM of the internal capsule adjacent to the right caudate nucleus that crete domain in transmembrane domain 1-2 of the DAT (Vaughan et were not present in COC-L or when all CD patients were compared al 2005). In an attempt to provide a 2-substituted benztropine pho- with CON. All patients showed lower FA in the substantia nigra and toaffinity label, analogous to RTI 82, MFZ 4-40, (Zou, et al. 2003) was globus pallidus that was right-lateralized and lower FA in the deep prepared as well as an additional compound in which the chain WM of the temporal lobe that was left-lateralized. Moreover, frontal length at the 2-position was extended by two atoms. The resulting lig- WM FA correlated positively with years of cocaine use and correlated and, MFZ 6-107, showed lower DAT affinity (IC50= 131 nM) as com- negatively with duration of abstinence across all subjects. Comparison pared to MFZ 4-40 (IC50= 55.6 nM), suggesting that an extended 2- of COC-S and COC-L subjects showed predominantly higher frontal position substituent was not well tolerated. Thus, a third lobe FA in COC-S. Four regions with significant changes in FA in 2-substituted analogue was derived using the linker length of MFZ 4- COC-S subjects, compared with COC-L, were also found in compar- 40 and the ester linkage of MFZ 6-107, which provided an improved isons of FA in COC-S vs. CON, suggesting that these regions showed synthetic strategy. In addition, a 3-beta-(3-iodo-4-azido-bipheny- reversible deficits in CD. Longitudinal testing confirmed that in- lene)-analogue of RTI 82 was recently synthesized. This latest addi- creased FA in COC-S in frontal WM regions was reversible, but sug- tion to our arsenal of DAT photoaffinity labels, JHC 2-48 (IC50= 15.1 gested that changes were more widespread. Analysis of tensor compo- nM) demonstrated the highest DAT binding affinity of any photoli- nents showed that reversible changes were due to increased Dra over gand prepared to date, as well as moderate affinity for SERT (IC50= time. ROIs placed in frontal WM confirmed both the cross-sectional 109) suggesting its potential utility in labeling SERT for analogous and longitudinal findings in frontal WM. protein structure studies. Discussion: This study showed reversible as well as persistent in- Discussion: Radioiodination of these remaining photoaffinity labels creases in frontal WM FA which must be viewed as deficits given the will provide the necessary tools for elucidating binding domains on impaired functional status of patients tested. Elucidation of the basis DAT (and SERT) of the tropane-based dopamine uptake inhibitors of these changes may provide insight into the anatomical mecha- using immunoprecipitation and proteolysis strategies. nisms in CD that may inform treatment. ACNP 2005 Annual Meeting S211 3. Prediction of Alcohol Problems Using A Prospective our QTLs for the MA sensitivity (LOD=4.5), a region that has previ- Longitudinal Design Including Genotype ously been associated with sensitivity to the stimulant effects of co- John I Nurnberger*, R Wiegand, L Bierut, K Bucholz, T Foroud, H caine. These data suggested the existence of an allele that influences Edenberg, E T Meyer, J Kramer, D Dick, W Reich, S Kuperman, V MA sensitivity by altering expression of Csnk1e. Human resutls: The Hesselbrock, A Goate, B Porjesz and H Begleiter primary outcome measure, subjects’ ratings of whether they felt a drug effect (Drug Effects Questionnaire; DEQ), revealed a significant Psychiatry, Indiana University School of Medicine, Indianapolis, effect (p = 0.01) of a non-coding SNP (rs135745) on the subjective IN, USA response to AMPH. Subjects with one or two copies of the C allele of Background: 1022 subjects from 448 families in the Collaborative rs135745 were more sensitive to the 10 mg dose of AMPH (p = Study of the Genetics of Alcoholism (COGA) were assessed at two 0.001). Subjects with different genotypes at this SNP also differed on time points separated by an interval of 4-5 years. The age of subjects secondary outcomes, including the “euphoria” scale of the ARCI, at at Time 2 was 17.4 + 3.4 years. At Time 2, 230 subjects were diagnosed the 10 mg dose. with DSM IV alcohol dependence or abuse by personal interview Discussion: These findings demonstrate a powerful translational ap- and/or interview of a parent about the subject. proach to studying pharmacogenetics in mice and humans, and offer Methods: Characteristics at Time 1 were used to predict affected sta- a road-map for future investigations of genetically determined differ- tus at Time 2.
Recommended publications
  • Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors
    Virginia Commonwealth University VCU Scholars Compass Theses and Dissertations Graduate School 2012 Antinociceptive Effects of Monoamine Reuptake Inhibitors in Assays of Pain-Stimulated and Pain-Depressed Behaviors Marisa Rosenberg Virginia Commonwealth University Follow this and additional works at: https://scholarscompass.vcu.edu/etd Part of the Medical Pharmacology Commons © The Author Downloaded from https://scholarscompass.vcu.edu/etd/2715 This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact [email protected]. ANTINOCICEPTIVE EFFECTS OF MONOAMINE REUPTAKE INHIBITORS IN ASSAYS OF PAIN-STIMULATED AND PAIN-DEPRESSED BEHAVIOR A thesis submitted in partial fulfillment of the requirements for the degree of Master of Science at Virginia Commonwealth University By Marisa B. Rosenberg Bachelor of Science, Temple University, 2008 Advisor: Sidney Stevens Negus, Ph.D. Professor, Department of Pharmacology/Toxicology Virginia Commonwealth University Richmond, VA May, 2012 Acknowledgement First and foremost, I’d like to thank my advisor Dr. Steven Negus, whose unwavering support, guidance and patience throughout my graduate career has helped me become the scientist I am today. His dedication to education, learning and the scientific process has instilled in me a quest for knowledge that I will continue to pursue in life. His thoroughness, attention to detail and understanding of pharmacology has been exemplary to a young person like me just starting out in the field of science. I’d also like to thank all of my committee members (Drs.
    [Show full text]
  • Cognition and Steroidogenesis in the Rhesus Macaque
    Cognition and Steroidogenesis in the Rhesus Macaque Krystina G Sorwell A DISSERTATION Presented to the Department of Behavioral Neuroscience and the Oregon Health & Science University School of Medicine in partial fulfillment of the requirements for the degree of Doctor of Philosophy November 2013 School of Medicine Oregon Health & Science University CERTIFICATE OF APPROVAL This is to certify that the PhD dissertation of Krystina Gerette Sorwell has been approved Henryk Urbanski Mentor/Advisor Steven Kohama Member Kathleen Grant Member Cynthia Bethea Member Deb Finn Member 1 For Lily 2 TABLE OF CONTENTS Acknowledgments ......................................................................................................................................................... 4 List of Figures and Tables ............................................................................................................................................. 7 List of Abbreviations ................................................................................................................................................... 10 Abstract........................................................................................................................................................................ 13 Introduction ................................................................................................................................................................. 15 Part A: Central steroidogenesis and cognition ............................................................................................................
    [Show full text]
  • The Human Carotid Body Expression of Oxygen Sensing and Signaling Genes of Relevance for Anesthesia
    PERIOPERATIVE MEDICINE Anesthesiology 2010; 113:1270–9 Copyright © 2010, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins The Human Carotid Body Expression of Oxygen Sensing and Signaling Genes of Relevance for Anesthesia Malin Jonsson Fagerlund, M.D., Ph.D.,* Jessica Kåhlin, M.D.,† Anette Ebberyd, B.M.A.,‡ Gunnar Schulte, Ph.D.,§ Souren Mkrtchian, M.D., Ph.D.,ʈ Lars I. Eriksson, M.D., Ph.D., F.R.C.A.# Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/113/6/1270/252613/0000542-201012000-00011.pdf by guest on 28 September 2021 ABSTRACT with DNA microarrays, real-time polymerase chain reaction, Background: Hypoxia is a common cause of adverse events and immunohistochemistry. in the postoperative period, where respiratory depression due Results: We found gene expression of the oxygen-sensing ϩ to residual effects of drugs used in anesthesia is an important pathway, heme oxygenase 2, and the K channels TASK ϩ underlying factor. General anesthetics and neuromuscular (TWIK-related acid sensitive K channel)-1 and BK (large- blocking agents reduce the human ventilatory response to conductance potassium channel). In addition, we show the hypoxia. Although the carotid body (CB) is the major oxygen expression of critical receptor subunits such as ␥-aminobu- ␣ ␤ ␥ sensor in humans, critical oxygen sensing and signaling path- tyric acid A ( 2, 3, and 2), nicotinic acetylcholine recep- ␣ ␣ ␤ ways have been investigated only in animals so far. Thus, the tors ( 3, 7, and 2), purinoceptors (A2A and P2X2), and aim of this study was to characterize the expression of key the dopamine D2 receptor. genes and localization of their products involved in the hu- Conclusions: In unique samples of the human CB, we here man oxygen sensing and signaling pathways with a focus on demonstrate presence of critical proteins in the oxygen-sens- receptor systems and ion channels of relevance in anesthesia.
    [Show full text]
  • Dopamine Reuptake Transporter (DAT) “Inverse Agonism” E Anovel 66 2 67 3 Hypothesis to Explain the Enigmatic Pharmacology of Cocaine 68 4 * 69 5 Q5 David J
    NP5526_proof ■ 24 June 2014 ■ 1/22 Neuropharmacology xxx (2014) 1e22 55 Contents lists available at ScienceDirect 56 57 Neuropharmacology 58 59 60 journal homepage: www.elsevier.com/locate/neuropharm 61 62 63 64 65 1 Dopamine reuptake transporter (DAT) “inverse agonism” e Anovel 66 2 67 3 hypothesis to explain the enigmatic pharmacology of cocaine 68 4 * 69 5 Q5 David J. Heal , Jane Gosden, Sharon L. Smith 70 6 71 RenaSci Limited, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK 7 72 8 73 9 article info abstract 74 10 75 11 76 Article history: The long held view is cocaine's pharmacological effects are mediated by monoamine reuptake inhibition. 12 Available online xxx However, drugs with rapid brain penetration like sibutramine, bupropion, mazindol and tesofensine, 77 13 which are equal to or more potent than cocaine as dopamine reuptake inhibitors, produce no discernable 78 14 Keywords: subjective effects such as drug “highs” or euphoria in drug-experienced human volunteers. Moreover 79 15 Cocaine they are dysphoric and aversive when given at high doses. In vivo experiments in animals demonstrate 80 16 Dopamine reuptake inhibitor that cocaine's monoaminergic pharmacology is profoundly different from that of other prescribed 81 Dopamine releasing agent 17 monoamine reuptake inhibitors, with the exception of methylphenidate. These findings led us to 82 Dopamine transporter fi 18 Inverse agonist conclude that the highly unusual, stimulant pro le of cocaine and related compounds, eg methylphe- 83 19 DAT inverse agonist nidate, is not mediated by monoamine reuptake inhibition alone. 84 We describe the experimental findings which suggest cocaine serves as a negative allosteric 20 Novel mechanism 85 21 modulator to alter the function of the dopamine reuptake transporter (DAT) and reverse its direction of fi 86 22 transport.
    [Show full text]
  • Structural Basis for Potentiation by Alcohols and Anaesthetics in a Ligand-Gated Ion Channel
    ARTICLE Received 10 Jul 2012 | Accepted 28 Feb 2013 | Published 16 Apr 2013 DOI: 10.1038/ncomms2682 Structural basis for potentiation by alcohols and anaesthetics in a ligand-gated ion channel Ludovic Sauguet1,2,3,4,*, Rebecca J. Howard5,w,*, Laurie Malherbe1,2,3,4,UiS.Lee5, Pierre-Jean Corringer3,4, R. Adron Harris5 & Marc Delarue1,2 Ethanol alters nerve signalling by interacting with proteins in the central nervous system, particularly pentameric ligand-gated ion channels. A recent series of mutagenesis experi- ments on Gloeobacter violaceus ligand-gated ion channel, a prokaryotic member of this family, identified a single-site variant that is potentiated by pharmacologically relevant concentra- tions of ethanol. Here we determine crystal structures of the ethanol-sensitized variant in the absence and presence of ethanol and related modulators, which bind in a transmembrane cavity between channel subunits and may stabilize the open form of the channel. Structural and mutagenesis studies defined overlapping mechanisms of potentiation by alcohols and anaesthetics via the inter-subunit cavity. Furthermore, homology modelling show this cavity to be conserved in human ethanol-sensitive glycine and GABA(A) receptors, and to involve residues previously shown to influence alcohol and anaesthetic action on these proteins. These results suggest a common structural basis for ethanol potentiation of an important class of targets for neurological actions of ethanol. 1 Unite´ de Dynamique Structurale des Macromole´cules, Institut Pasteur, F-75015 Paris, France. 2 UMR 3258, Centre National de la Recherche Scientifique, F-75015 Paris, France. 3 Groupe Re´cepteurs-Canaux, Institut Pasteur, F-75015 Paris, France. 4 Unite´ de Recherche Associe´e 2182, Centre National de la Recherche Scientifique, F-75015 Paris, France.
    [Show full text]
  • Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors
    International Journal of Molecular Sciences Article Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors Hana Kubová 1,* , Zde ˇnkaBendová 2,3 , Simona Moravcová 2,3 , Dominika Paˇcesová 2,3, Luisa Rocha 4 and Pavel Mareš 1 1 Institute of Physiology, Academy of Sciences of the Czech Republic, 14220 Prague, Czech Republic; [email protected] 2 Faculty of Science, Charles University, 12800 Prague, Czech Republic; [email protected] (Z.B.); [email protected] (S.M.); [email protected] (D.P.) 3 National Institute of Mental Health, 25067 Klecany, Czech Republic 4 Pharmacobiology Department, Center of Research and Advanced Studies, Mexico City 14330, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +420-2-4106-2565 Received: 31 March 2020; Accepted: 28 April 2020; Published: 30 April 2020 Abstract: Benzodiazepines (BZDs) are widely used in patients of all ages. Unlike adults, neonatal animals treated with BZDs exhibit a variety of behavioral deficits later in life; however, the mechanisms underlying these deficits are poorly understood. This study aims to examine whether administration of clonazepam (CZP; 1 mg/kg/day) in 7–11-day-old rats affects Gama aminobutyric acid (GABA)ergic receptors in both the short and long terms. Using RT-PCR and quantitative autoradiography, we examined the expression of the selected GABAA receptor subunits (α1, α2, α4, γ2, and δ) and the GABAB B2 subunit, and GABAA, benzodiazepine, and GABAB receptor binding 48 h, 1 week, and 2 months after treatment discontinuation. Within one week after CZP cessation, the expression of the α2 subunit was upregulated, whereas that of the δ subunit was downregulated in both the hippocampus and cortex.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • The Role of GABRA2 in Risk for Conduct Disorder and Alcohol and Drug Dependence Across Developmental Stages
    Behavior Genetics, Vol. 36, No. 4, July 2006 (Ó 2006) DOI: 10.1007/s10519-005-9041-8 The Role of GABRA2 in Risk for Conduct Disorder and Alcohol and Drug Dependence across Developmental Stages Danielle M. Dick,1,9 Laura Bierut,1 Anthony Hinrichs,1 Louis Fox,1 Kathleen K. Bucholz,1 John Kramer,2 Samuel Kuperman,2 Victor Hesselbrock,3 Marc Schuckit,4 Laura Almasy,5 Jay Tischfield,6 Bernice Porjesz,7 Henri Begleiter,7 John Nurnberger Jr.,8 Xiaoling Xuei,8 Howard J. Edenberg,8 and Tatiana Foroud8 Received Apr. 28 2005—Final Dec. 22 2005 We use findings from the behavior genetics literature about how genetic factors (latently) influence alcohol dependence and related disorders to develop and test hypotheses about the risk associated with a specific gene, GABRA2, across different developmental stages. This gene has previously been associated with adult alcohol dependence in the Collaborative Study of the Genetics of Alcoholism (COGA) sample [Edenberg, H. J., Dick, D. M., Xuei, X., Tian, H., Almasy, L., Bauer, L. O., Crowe, R., Goate, A., Hesselbrock, V., Jones, K. A., Kwon, J., Li, T. K., Nurnberger Jr., J. I., OÕConnor, S. J., Reich, T., Rice, J., Schuckit, M., Porjesz, B., Foroud, T., and Begleiter, H. (2004). Am. J. Hum. Genet. 74:705–714] and other studies [Covault, J., Gelernter, J., Hesselbrock, V., Nellissery, M., and Kranzler, H. R. (2004). Am. J. Med. Genet. B Neuropsychiatr. Genet. 129B:104–109; Lappalainen, J., Krupitsky, E., Remizov, M., Pchelina, S., Taraskina, A., Zvartau, E., Somberg, L. K., Covault, J., Kranzler, H. R., Krystal, J., and Gelernter, J.
    [Show full text]
  • YTN Ci Y COOCH3 --Al-E- F 7.1% F 5 6
    USOO5853696A United States Patent (19) 11 Patent Number: 5,853,696 Elmaleh et al. (45) Date of Patent: Dec. 29, 1998 54 SUBSTITUTED 2-CARBOXYALKYL-3 Carroll et al., “Synthesis, Ligand Binding, QSAR, and (FLUOROPHENYL)-8-(3-HALOPROPEN-2- CoMFA Study . , Journal of Medicinal Chemistry YL) NORTROPANES AND THEIR USE AS 34:2719-2725, 1991. IMAGING AGENTS FOR Madras et al., “N-Modified Fluorophenyltropane Analogs. NEURODEGENERATIVE DISORDERS ... ", Pharmcology, Biochemistry & Behavior 35:949–953, 1990. 75 Inventors: David R. Elmaleh; Bertha K. Madras, Milius et al., “Synthesis and Receptor Binding of N-Sub both of Newton; Peter Meltzer, stituted Tropane Derivatives . , Journal of Medicinal Lexington; Robert N. Hanson, Newton, Chemistry 34:1728-1731, 1991. all of Mass. Boja et al. “New, Potent Cocaine Analogs: Ligand Binding 73 Assignees: Organix, Inc., Woburn; The General and Transport Studies in Rat Striatum' European J. of Hospital Corporation, Boston; The Pharmacology, 184:329–332 (1990). President and Fellows of Harvard Brownell et al. *Use of C-11 College, Cambridge; Northeastern 2B-Carbomethoxy-3B-4-Fluorophenyl Tropane (C-11 University, Boston, all of Mass. CFT) in Studying Dopamine Fiber Loss in a Primate Model of Parkinsonism” J. Nuclear Med. Abs., 33:946 (1992). 21 Appl. No.: 605,332 Canfield et al. “Autoradiographic Localization of Cocaine Binding Sites by HICFT (I HIWIN 35,428) in the 22 Filed: Feb. 20, 1996 Monkey Brain” Synapse, 6:189-195 (1990). Carroll et al. “Probes for the Cocaine Receptor. Potentially Related U.S. Application Data Irreversible Ligands for the Dopamine Transporter” J. Med. 62 Division of Ser. No. 142.584, Oct.
    [Show full text]
  • Current Topics in Behavioral Neurosciences
    Current Topics in Behavioral Neurosciences Series Editors Mark A. Geyer, La Jolla, CA, USA Bart A. Ellenbroek, Wellington, New Zealand Charles A. Marsden, Nottingham, UK For further volumes: http://www.springer.com/series/7854 About this Series Current Topics in Behavioral Neurosciences provides critical and comprehensive discussions of the most significant areas of behavioral neuroscience research, written by leading international authorities. Each volume offers an informative and contemporary account of its subject, making it an unrivalled reference source. Titles in this series are available in both print and electronic formats. With the development of new methodologies for brain imaging, genetic and genomic analyses, molecular engineering of mutant animals, novel routes for drug delivery, and sophisticated cross-species behavioral assessments, it is now possible to study behavior relevant to psychiatric and neurological diseases and disorders on the physiological level. The Behavioral Neurosciences series focuses on ‘‘translational medicine’’ and cutting-edge technologies. Preclinical and clinical trials for the development of new diagostics and therapeutics as well as prevention efforts are covered whenever possible. Cameron S. Carter • Jeffrey W. Dalley Editors Brain Imaging in Behavioral Neuroscience 123 Editors Cameron S. Carter Jeffrey W. Dalley Imaging Research Center Department of Experimental Psychology Center for Neuroscience University of Cambridge University of California at Davis Downing Site Sacramento, CA 95817 Cambridge CB2 3EB USA UK ISSN 1866-3370 ISSN 1866-3389 (electronic) ISBN 978-3-642-28710-7 ISBN 978-3-642-28711-4 (eBook) DOI 10.1007/978-3-642-28711-4 Springer Heidelberg New York Dordrecht London Library of Congress Control Number: 2012938202 Ó Springer-Verlag Berlin Heidelberg 2012 This work is subject to copyright.
    [Show full text]
  • Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types
    (19) TZZ ¥Z_T (11) EP 2 380 595 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 26.10.2011 Bulletin 2011/43 A61K 47/48 (2006.01) C12N 15/11 (2006.01) A61P 25/00 (2006.01) A61K 49/00 (2006.01) (2006.01) (21) Application number: 10382087.4 A61K 51/00 (22) Date of filing: 19.04.2010 (84) Designated Contracting States: • Alvarado Urbina, Gabriel AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Nepean Ontario K2G 4Z1 (CA) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • Bortolozzi Biassoni, Analia Alejandra PT RO SE SI SK SM TR E-08036, Barcelona (ES) Designated Extension States: • Artigas Perez, Francesc AL BA ME RS E-08036, Barcelona (ES) • Vila Bover, Miquel (71) Applicant: Nlife Therapeutics S.L. 15006 La Coruna (ES) E-08035, Barcelona (ES) (72) Inventors: (74) Representative: ABG Patentes, S.L. • Montefeltro, Andrés Pablo Avenida de Burgos 16D E-08014, Barcelon (ES) Edificio Euromor 28036 Madrid (ES) (54) Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types (57) The invention provides a conjugate comprising nucleuc acid toi cell of interests and thus, for the treat- (i) a nucleic acid which is complementary to a target nu- ment of diseases which require a down-regulation of the cleic acid sequence and which expression prevents or protein encoded by the target nucleic acid as well as for reduces expression of the target nucleic acid and (ii) a the delivery of contrast agents to the cells for diagnostic selectivity agent which is capable of binding with high purposes.
    [Show full text]
  • The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder
    REVIEW The Roles of Dopamine and Noradrenaline in the Pathophysiology and Treatment of Attention-Deficit/ Hyperactivity Disorder Natalia del Campo, Samuel R. Chamberlain, Barbara J. Sahakian, and Trevor W. Robbins Through neuromodulatory influences over fronto-striato-cerebellar circuits, dopamine and noradrenaline play important roles in high-level executive functions often reported to be impaired in attention-deficit/hyperactivity disorder (ADHD). Medications used in the treatment of ADHD (including methylphenidate, dextroamphetamine and atomoxetine) act to increase brain catecholamine levels. However, the precise prefrontal cortical and subcortical mechanisms by which these agents exert their therapeutic effects remain to be fully specified. Herein, we review and discuss the present state of knowledge regarding the roles of dopamine (DA) and noradrenaline in the regulation of cortico- striatal circuits, with a focus on the molecular neuroimaging literature (both in ADHD patients and in healthy subjects). Recent positron emission tomography evidence has highlighted the utility of quantifying DA markers, at baseline or following drug administration, in striatal subregions governed by differential cortical connectivity. This approach opens the possibility of characterizing the neurobiological underpinnings of ADHD (and associated cognitive dysfunction) and its treatment by targeting specific neural circuits. It is anticipated that the application of refined and novel positron emission tomography methodology will help to disentangle the overlapping and dissociable contributions of DA and noradrenaline in the prefrontal cortex, thereby aiding our understanding of ADHD and facilitating new treatments. Key Words: Attention-deficit/hyperactivity disorder, dopamine, DA and NA in the pathophysiology of ADHD, with a focus on the frontostriatal circuits, nigrostriatal projections, noradrenaline, pos- molecular neuroimaging literature.
    [Show full text]